HSP60 may predict good pathological response to neoadjuvant chemoradiotherapy in bladder cancer

Japanese Journal of Clinical Oncology

Volumn 37, Issue 1, 2007, Pages 56-61

  Urushibara, Masayasu ^a   Kageyama, Yukio ^a,b   Akashi, Takumi ^a   Otsuka, Yukihiro ^a   Takizawa, Touichiro ^a   Koike, Morio ^a   Kihara, Kazunori ^a  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^b SAITAMA CANCER CENTER   (Japan)

Author keywords

Chemo urology; Patho molecular; Prognostic factors; Urologic radioncology; Urologic surgery

Indexed keywords

CISPLATIN; HEAT SHOCK PROTEIN; HEAT SHOCK PROTEIN 27; HEAT SHOCK PROTEIN 60; HEAT SHOCK PROTEIN 70; HEAT SHOCK PROTEIN 90; PROTEIN P53;

ADULT; AGED; ARTICLE; BLADDER CANCER; CANCER ADJUVANT THERAPY; CANCER INVASION; CANCER SURVIVAL; CONTROLLED STUDY; CYSTECTOMY; DRUG DOSE REDUCTION; FEMALE; HIGH RISK PATIENT; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PATIENT CODING; PREOPERATIVE CARE; PROGNOSIS; PROTEIN EXPRESSION; RADIATION DOSE; SURVIVAL RATE; SURVIVAL TIME; TREATMENT RESPONSE;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BIOLOGICAL MARKERS; BIOPSY; CHAPERONIN 60; FEMALE; HEAT-SHOCK PROTEINS; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; URINARY BLADDER NEOPLASMS;

EID: 34447624723     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyl121     Document Type: Article

References (21)

1. Winquist E, Kirchner TS, Segal R, Chin J, Lukka H. Neoadjuvant chemotherapy for transitional cell carcinoma of the bladder: A systematic review and meta-analysis, J Urol 2004;171:561-9.
2. de la Rosa F, Garcia-Carbonero R, Passas J, Rosino A, Lianes P, Paz-Ares L. Primary cisplatin, methotrexate and vinblastine chemotherapy with selective bladder preservation for muscle invasive carcinoma of the bladder: Long-term followup of a prospective study. J Urol 2002;167:2413-8.
3. Sternberg CN, Pansadoro V, Calabro F, Schnetzer S, Giannarelli D, Emiliozzi P, et al. Can patient selection for bladder preservation be based on response to chemotherapy? Cancer 2003;97:1644-52.
4. Kageyama Y, Yokoyama M, Sakai Y, Saito K, Koga F, Yano M, et al. Favorable outcome of preoperative low dose chemoradiotherapy against muscle-invasive bladder cancer. Am J Clin Oncol 2003;26:504-7.
5. Jolly C, Morimoto RI. Role of the heat shock response and molecular chaperones in oncogenesis and cell death. J Natl Cancer Inst 2000;92:1564-72.
6. Devaja O, King RJ, Papadopoulos A, Raju KS. Heat-shock protein 27 (HSP27) and its role in female reproductive organs. Eur J Gynaecol Oncol 1997;18:16-22.
7. Lin KM, Lin B, Lian IY, Mestril R, Scheffler IE, Dillmann WH. Combined and individual mitochondrial HSP60 and HSP10 expression in cardiac myocytes protects mitochondrial function and prevents apoptotic cell deaths induced by simulated ischemia-reoxygenation. Circulation 2001;103:1787-92.
8. Nylandsted J, Brand K, Jaattela M. Heat shock protein 70 is required for the survival of cancer cells. Ann N York Acad Sci 2000;926:122-5.
9. Wyllie AH, Kerr JP, Currie AR. Cell death: The significance of apoptosis. Int Rev Cytol 1080;68:251-306.
10. Ferrarini M, Heltai S, Zocchi MR, Rugarli C. Unusual expression and localization of heat-shock proteins in human tumor cells. Int J Cancer 1992;51:613-9.
11. Cardillo MR, Sale P, Di Silverio F. Heat shock protein-90, IL-6 and IL-10 in bladder cancer. Anticancer Res 2000;20:4579-83.
12. Lebret T, Watson RWG, Molinie V, O'Neill A, Gabriel C, Fitzpatrick JM, et al. Heat shock proteins HSP27, HSP60, HSP70, and HSP90. Expression in bladder carcinoma. Cancer 2003;98:970-7.
13. Syrigos KN, Harrington KJ, Karayiannakis AJ, Sekara E, Chatziyianni E, Syrigou EI, et al. Clinical significance of heat shock protein-70 expression in bladder cancer. Urology 2003;61:677-80.
14. International Union Against Cancer. Urinary bladder. In: Hermanek P, Hutter RVP, Sobin LH, Wagner G, Wittekind CH, editors. TNM Atlas: illustrated guide to the TNM/pTNM classification of malignant tumours, 4th edn. Heidelberg: Springer 1997; 309-14.
15. Japanese Urological Association and the Japanese Society of Pathology. Histological grading and criteria of therapeutic effect. In: Moridono S, Murai M, Akaza H, Oshima S, Ogawa O, Kagawa T, et al. editors. General rule for clinical and pathological studies on bladder cancer, 3rd edn. Tokyo: Kanehara Press 2001;56-84 (in Japanese).
16. Esrig D, Elmajian D, Groshen S, Freeman JA, Stein JP, Chen SC, et al. Accumulation of nuclear p53 and tumor progression in bladder cancer. N Engl J Med 1994;331:1259-64.
17. Faried A, Sohda M, Nakajima M, Miyazaki T, Kato H, Kuwano H. Expression of heat-shock protein Hsp60 correlated with the apoptotic index and patient prognosis in human oesophageal squamous cell carcinoma. Eur J Cancer 2004;40:2804-11.
18. Zlotta AR, Drowart A, Huygen K, De Bruyn J, Shekarsarai H, Decock M, et al. Humoral response against heat shock proteins and other mycobacterial antigens after intravesical treatment with bacille Calmette - Guerin (BCG) in patients with superficial bladder cancer. Clin Exp Immunol 1997;109-157-65.
19. Cordon-Cardo C. Mutations of cell cycle regulators. Biological and clinical implications for human neoplasia. Am J Pathol 1995;147:545-60.
20. Rodel C, Grabenbauer GG, Rodel F, Birkenhake S, Kuhn R, Martus P, et al Apoptosis, p53, bcl-2 and Ki-67 in invasive bladder carcinoma: Possible predictors for response to radiochemotheraphy and successful bladder preservation. Int J Radiat Oncol Biol Phys 2000;46:1213-21.
21. Chakravarti A, Winter K, Wu CL, Kaufman D, Hammond E, Parliament M, et al. Expression of the epidermal growth factor receptor and Her-2 are predictors of favorable outcome and reduced complete response rates, respectively, in patients with muscle-invading bladder cancers treated by concurrent radiation and cisplatin-based chemotherapy: A report from the radiation therapy oncology group. Int J Radiat Oncol Biol Phys 2005;62:309-17.